The Ratio of Serum Testosterone-to-Prostate Specific Antigen Predicts Prostate Cancer in Hypogonadal Men

Journal of Urology

Volumn 179, Issue 5, 2008, Pages 1741-1745

  Rhoden, Ernani Luis ^a   Riedner, Charles Edison ^b   Morgentaler, Abraham ^c  

^a Federal School of Medical Sciences of Porto Alegre   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Men's Health Boston   (United States)

Author keywords

hypogonadism; prostate; prostate specific antigen; prostatic neoplasms; testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; ROC CURVE; TESTOSTERONE BLOOD LEVEL;

BIOPSY, NEEDLE; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 41749098807     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.01.045     Document Type: Article

References (16)

1. Rhoden E.L., and Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350 (2004) 482
2. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 50 (2006) 935
3. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293
4. Morgentaler A. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol 52 (2007) 623
5. Hoffman M., DeWolf W.C., and Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824
6. Schatzl G., Madersbacher S., Thurridl T., Waldmüller J., Kramer G., Haitel A., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 (2001) 52
7. San Francisco I.F., Regan M.M., Dewolf W.C., and Olumi A.F. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 175 (2006) 1341
8. Massengill J.C., Sun L., Moul J.W., Wu H., McLeod D.G., Amling C., et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169 (2003) 1670
9. Teloken C., Da Ros C.T., Caraver F., Weber F.A., Cavalheiro A.P., and Graziottin T.M. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 174 (2005) 2178
10. Ribeiro M., Ruff P., and Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 20 (1997) 605
11. Morgentaler A., and Rhoden E.L. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology 68 (2006) 1263
12. Morgentaler A. New concepts regarding the relationship of testosterone and prostate cancer. Fut Oncol 3 (2007) 123
13. Karamanolakis D., Lambou T., Bogdanos J., Milathianakis C., Sourla A., Lembessis P., et al. Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (greater than or =3.0 and less than 10.0 ng/ml). Anticancer Res 26 (2006) 3159
14. Crawford E.D., Barqawi A.B., O'Donnell C., and Morgentaler A. The association of time of day and serum testosterone concentration in a large screening population. BJU Int 100 (2007) 509
15. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4 ng per milliliter. N Eng J Med 350 (2004) 2239
16. Nadler R.B., Loeb S., Roehl K.A., Antenor J.A., Eggener S., and Catalona W.J. Use of 2.6 ng/ml PSA prompt for biopsy in men older than 60 years. J Urol 174 (2005) 2154